Soleno Therapeutics Inc
SLNO41.510USD
-0.030-0.07%
Close 01/13, 16:00（ET）Quotes delayed by 15 min
2.23BMarket Cap
LossP/E TTM
More Details of Soleno Therapeutics Inc Company
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Soleno Therapeutics Inc Info
Ticker SymbolSLNO
Company nameSoleno Therapeutics Inc
IPO dateOct 23, 2014
CEOBhatnagar (Anish)
Number of employees92
Security typeOrdinary Share
Fiscal year-endOct 23
Address100 Marine Parkway, Suite 400
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94065
Phone16502138444
Websitehttps://soleno.life/
Ticker SymbolSLNO
IPO dateOct 23, 2014
CEOBhatnagar (Anish)
Company Executives of Soleno Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
88.66K
-2013.00%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
27.24K
-904.00%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+3991.00%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+3991.00%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+3991.00%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
10.49K
+3991.00%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Independent Director
Independent Director
10.05K
+10046.00%
Ms. Patricia C. Hirano
Ms. Patricia C. Hirano
Vice President - Regulatory Affairs
Vice President - Regulatory Affairs
5.91K
-904.00%
Dr. Anish Bhatnagar, M.D.
Dr. Anish Bhatnagar, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
88.66K
-2013.00%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
27.24K
-904.00%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+3991.00%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+3991.00%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+3991.00%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
10.49K
+3991.00%
Revenue Breakdown
FY2025Q3
FY2025Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
66.02M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 10
Updated: Sat, Jan 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.15%
Janus Henderson Investors
11.28%
T. Rowe Price Associates, Inc.
7.16%
BlackRock Institutional Trust Company, N.A.
5.47%
The Vanguard Group, Inc.
5.21%
Other
58.73%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.15%
Janus Henderson Investors
11.28%
T. Rowe Price Associates, Inc.
7.16%
BlackRock Institutional Trust Company, N.A.
5.47%
The Vanguard Group, Inc.
5.21%
Other
58.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
49.45%
Investment Advisor/Hedge Fund
44.49%
Hedge Fund
22.96%
Venture Capital
5.33%
Individual Investor
1.66%
Research Firm
1.50%
Bank and Trust
0.78%
Pension Fund
0.34%
Sovereign Wealth Fund
0.11%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
456
67.19M
125.10%
+4.13M
2025Q3
416
58.51M
108.94%
-3.11M
2025Q2
384
58.69M
110.44%
+1.14M
2025Q1
373
57.15M
113.59%
-442.82K
2024Q4
313
53.26M
117.76%
+3.04M
2024Q3
277
49.14M
121.09%
-377.00K
2024Q2
234
44.76M
117.95%
+4.14M
2024Q1
189
36.54M
114.10%
-1.05M
2023Q4
146
32.09M
102.81%
+3.37M
2023Q3
107
21.08M
166.08%
+14.34M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
6.53M
12.15%
+3.30M
+102.30%
Sep 30, 2025
Janus Henderson Investors
6.06M
11.28%
+748.33K
+14.10%
Sep 30, 2025
T. Rowe Price Associates, Inc.
3.85M
7.16%
+426.98K
+12.49%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.94M
5.47%
+432.30K
+17.24%
Sep 30, 2025
The Vanguard Group, Inc.
2.80M
5.21%
+317.29K
+12.79%
Sep 30, 2025
Avoro Capital Advisors LLC
2.58M
4.8%
+527.78K
+25.75%
Sep 30, 2025
Wellington Management Company, LLP
2.31M
4.3%
+1.69M
+272.30%
Sep 30, 2025
Vivo Capital, LLC
2.28M
4.24%
-1.68M
-42.44%
Sep 30, 2025
State Street Investment Management (US)
2.17M
4.05%
+768.05K
+54.67%
Sep 30, 2025
Invesco Advisers, Inc.
1.49M
2.78%
+1.02M
+213.97%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
State Street SPDR S&P Biotech ETF
1.52%
Harbor Health Care ETF
0.95%
Direxion Daily S&P Biotech Bull 3X Shares
0.93%
JPMorgan Healthcare Leaders ETF
0.71%
Virtus LifeSci Biotech Clinical Trials ETF
0.57%
Pacer WealthShield ETF
0.24%
VictoryShares US Small Mid Cap Value Momentum ETF
0.2%
T Rowe Price Small-Mid Cap ETF
0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.17%
Fidelity Fundamental Small-Mid Cap ETF
0.16%
View more
State Street SPDR S&P Biotech ETF
Proportion1.52%
Harbor Health Care ETF
Proportion0.95%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.93%
JPMorgan Healthcare Leaders ETF
Proportion0.71%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.57%
Pacer WealthShield ETF
Proportion0.24%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.2%
T Rowe Price Small-Mid Cap ETF
Proportion0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.17%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Date
Type
Ratio
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
FAQs
Who are the top five shareholders of Soleno Therapeutics Inc?
The top five shareholders of Soleno Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 6.53M shares, accounting for 12.15% of the total shares.
Janus Henderson Investors holds 6.06M shares, accounting for 11.28% of the total shares.
T. Rowe Price Associates, Inc. holds 3.85M shares, accounting for 7.16% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.94M shares, accounting for 5.47% of the total shares.
The Vanguard Group, Inc. holds 2.80M shares, accounting for 5.21% of the total shares.
Fidelity Management & Research Company LLC holds 6.53M shares, accounting for 12.15% of the total shares.
Janus Henderson Investors holds 6.06M shares, accounting for 11.28% of the total shares.
T. Rowe Price Associates, Inc. holds 3.85M shares, accounting for 7.16% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.94M shares, accounting for 5.47% of the total shares.
The Vanguard Group, Inc. holds 2.80M shares, accounting for 5.21% of the total shares.
What are the top three shareholder types of Soleno Therapeutics Inc?
The top three shareholder types of Soleno Therapeutics Inc are:
Fidelity Management & Research Company LLC
Janus Henderson Investors
T. Rowe Price Associates, Inc.
Fidelity Management & Research Company LLC
Janus Henderson Investors
T. Rowe Price Associates, Inc.
How many institutions hold shares of Soleno Therapeutics Inc (SLNO)?
As of 2025Q4, 456 institutions hold shares of Soleno Therapeutics Inc, with a combined market value of approximately 67.19M, accounting for 125.10% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 16.16%.
What is the biggest source of revenue for Soleno Therapeutics Inc?
In FY2025Q3, the -- business generated the highest revenue for Soleno Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
